Acerus Announces Voting Results for the 2021 Annual Meeting
15 June 2021 - 7:30AM
Acerus Pharmaceuticals Corporation (“
Acerus”)
(TSX: ASP; OTCQB: ASPCF) today announced the voting results from
its annual meeting of shareholders held on June 14, 2021 in
Toronto, Ontario. The total number of shares represented in person
or by proxy at the meeting was 1,408,673,111, representing 91.62%
of the total issued and outstanding Acerus shares.
Election of Directors
The six (6) candidates nominated for election to
the Acerus board of directors and listed in Acerus’ management
information circular dated April 29, 2021, were elected by a
majority of the votes cast by shareholders present in person or
represented by proxy at the meeting. The voting results are as
follows:
Name |
Votes For (%) |
Votes Withheld (%) |
Ian O. Ihnatowycz |
1,400,976,358 (99.66%) |
4,722,241 (0.34%) |
Geoff Cotton |
1,400,919,128 (99.66%) |
4,779,471 (0.34%) |
Borys Chabursky |
1,400,891,128 (99.66%) |
4,807,471 (0.34%) |
Stephen Gregory |
1,400,891,128 (99.66%) |
4,807,471 (0.34%) |
Scott Leckie |
1,403,535,730 (99.85%) |
2,162,869 (0.15%) |
Edward Gudaitis |
1,401,004,358 (99.66%) |
4,694,241 (0.33%) |
Appointment of Auditors
Acerus announced today that its shareholders
have approved the re‐appointment of PricewaterhouseCoopers LLP as
the Auditor of Acerus to hold office until the next annual meeting
of shareholders.
Share Consolidation
Acerus announced today that its shareholders
have approved a consolidation of the issued and outstanding common
shares of the Company on the basis of one (1) post-consolidation
common share for up to two hundred (200) pre-consolidation common
shares if, and at such time following the meeting, as the board of
directors so determines. The proposed share consolidation was
described in detail in the Management Information Circular dated
April 29, 2021 and available on SEDAR (the “Management Information
Circular”), and the special resolution was also set forth in the
Management Information Circular.
Although approval for the share consolidation
was approved at this meeting, such share consolidation would
ultimately become effective at a future date as determined by the
board of directors and at a ratio of up to two hundred (200) as
determined by the board of directors.
About
Acerus
Acerus Pharmaceuticals Corporation is a
Canadian-based specialty pharmaceutical company focused on the
commercialization and development of innovative prescription
products that improve patient experience, with a primary focus in
the field of men’s health. The Company commercializes its products
via its own salesforce in the United States and Canada, and through
a global network of licensed distributors in other territories.
Acerus’ shares trade on TSX under the symbol ASP
and on OTCQB under the symbol ASPCF. For more information, visit
www.aceruspharma.com and follow us on Twitter and LinkedIn.
Notice regarding
forward‐looking statements
Information in this press release that is not
current or historical factual information may constitute forward
looking information within the meaning of securities laws. Implicit
in this information are assumptions regarding our future
operational results. These assumptions, although considered
reasonable by the company at the time of preparation, may prove to
be incorrect. Readers are cautioned that actual performance of the
company is subject to a number of risks and uncertainties, and
could differ materially from what is currently expected as set out
above. For more exhaustive information on these risks and
uncertainties you should refer to our annual information form dated
March 10, 2021 which is available at www.sedar.com.
Forward-looking information contained in this press release is
based on our current estimates, expectations and projections, which
we believe are reasonable as of the current date. You should not
place undue importance on forward-looking information and should
not rely upon this information as of any other date. While we may
elect to, we are under no obligation and do not undertake to update
this information at any particular time, whether as a result of new
information, future events or otherwise, except as required by
applicable securities law.
Company Contactir@aceruspharma.com
Investor Relations ContactChris WittyAcerus
Investor Relations (646) 438-9385cwitty@darrowir.com
Acerus Pharmaceuticals (TSX:ASP)
Historical Stock Chart
From Apr 2024 to May 2024
Acerus Pharmaceuticals (TSX:ASP)
Historical Stock Chart
From May 2023 to May 2024